Concurrent Chemoradiotherapy with Cisplatin and Docetaxel for Advanced Head and Neck Cancer Multicentric Phase II Study
Not Applicable
- Conditions
- Head and neck squamous cell carcinoma at stage III and IV
- Registration Number
- JPRN-C000000306
- Lead Sponsor
- Department of Otorhinolaryngology and Head and Neck Surgery, Osaka University School of Medicine
- Brief Summary
CR rate 71%, 2-year overall survival 82%, and 4-year overall survival 68% for technically resectable disease. CR rate 45%, 2-year overall survival 58%, and 4-year overall survival 44% for technically unresectable disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
1) interstitial pneumonia or pulmonary fibrosis evidenced by chest X-ray and/or chest CT 2) major heart/lung disorders, or uncontrolled diabetes mellitus 3) distant metastases or second primary cancer except when there has been no evidence of the disease for more than 24 months without any treatment and when the disease is superficial 4) major pulmonary effusion or ascites 5) neuropathy or edema 6) pregnancy or lactation 7) history of major allergy to medicine 8) long use of steroid
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Survival rate, organ preservation rate, safety